Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Johnson

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Journal of Medicinal Chemistry|March 27, 2010
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitorThomas D Penning, Gui-Dong Zhu, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|June 11, 2008
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Blood|January 9, 2007
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemiaDeepa B Shankar, Junling Li, Paul Tapang, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|June 9, 2006
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activityBruce G Szczepankiewicz, Christi Kosogof, Lissa T J Nelson, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|March 18, 2015
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitorsMichael A Brodney, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|April 12, 2007
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channelJürgen Dinges, Daniel H Albert, Lee D Arnold, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Journal of Medicinal Chemistry|March 27, 2010
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitorThomas D Penning, Gui-Dong Zhu, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|June 11, 2008
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Blood|January 9, 2007
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemiaDeepa B Shankar, Junling Li, Paul Tapang, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|June 9, 2006
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activityBruce G Szczepankiewicz, Christi Kosogof, Lissa T J Nelson, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|March 18, 2015
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitorsMichael A Brodney, Elizabeth M Beck, Christopher R Butler, et al.
Journal of Medicinal Chemistry|April 12, 2007
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channelJürgen Dinges, Daniel H Albert, Lee D Arnold, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
Pageof 13